S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in
NASDAQ:OLMA

Olema Pharmaceuticals Stock Forecast, Price & News

$39.38
-1.05 (-2.60 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.10
Now: $39.38
$40.87
50-Day Range
$39.92
MA: $45.28
$53.64
52-Week Range
$35.73
Now: $39.38
$60.27
Volume102,793 shs
Average Volume92,047 shs
Market Capitalization$1.52 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OLMA
CUSIPN/A
CIKN/A
Phone415-651-3316
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.52 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

209th out of 1,968 stocks

Pharmaceutical Preparations Industry

103rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$39.38
-1.05 (-2.60 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OLMA News and Ratings via Email

Sign-up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Olema Pharmaceuticals (NASDAQ:OLMA) Frequently Asked Questions

Is Olema Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Olema Pharmaceuticals stock.
View analyst ratings for Olema Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Olema Pharmaceuticals?

Wall Street analysts have given Olema Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Olema Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for OLMA?

4 equities research analysts have issued twelve-month price objectives for Olema Pharmaceuticals' shares. Their forecasts range from $52.00 to $70.00. On average, they anticipate Olema Pharmaceuticals' stock price to reach $60.67 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts' price targets for Olema Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Olema Pharmaceuticals' key executives?

Olema Pharmaceuticals' management team includes the following people:
  • Dr. Cyrus L. Harmon Ph.D., CTO & Director (Age 51, Pay $300k)
  • Dr. Peter J. Kushner Ph.D., Chief Scientific Officer (Age 83, Pay $200k)
  • Dr. David C. Myles, Chief Devel. Officer (Age 59, Pay $200k)
  • Dr. Sean P. Bohen, Pres, CEO & Director (Age 55)
  • Mr. Shane William Charles Kovacs M.B.A., COO & CFO (Age 47)
  • Mr. John B. Moriarty Jr., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 53)
  • Mr. Kinney Horn, Chief Bus. Officer (Age 47)
  • Dr. Pamela M. Klein B.A., M.D., Chief Medical Officer (Age 60)
  • Dr. Leslie Hodges Gallagher Ph.D., Sr. VP of Discovery Biology

Who are some of Olema Pharmaceuticals' key competitors?

When did Olema Pharmaceuticals IPO?

(OLMA) raised $170 million in an IPO on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

What is Olema Pharmaceuticals' stock symbol?

Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA."

When does the company's lock-up period expire?

Olema Pharmaceuticals' lock-up period expires on Tuesday, May 18th. Olema Pharmaceuticals had issued 11,000,000 shares in its public offering on November 19th. The total size of the offering was $209,000,000 based on an initial share price of $19.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.45%), Avoro Capital Advisors LLC (2.28%), BlackRock Inc. (1.78%), Orbimed Advisors LLC (1.69%), Hillhouse Capital Advisors LTD. (1.61%) and Avidity Partners Management LP (0.70%). Company insiders that own Olema Pharmaceuticals stock include Cormorant Asset Management, Lp and G Walmsley Graham.
View institutional ownership trends for Olema Pharmaceuticals
.

Which major investors are buying Olema Pharmaceuticals stock?

OLMA stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Avoro Capital Advisors LLC, BlackRock Inc., Orbimed Advisors LLC, Hillhouse Capital Advisors LTD., Avidity Partners Management LP, Artal Group S.A., and Federated Hermes Inc.. Company insiders that have bought Olema Pharmaceuticals stock in the last two years include Cormorant Asset Management, Lp, and G Walmsley Graham.
View insider buying and selling activity for Olema Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Olema Pharmaceuticals' stock price today?

One share of OLMA stock can currently be purchased for approximately $39.38.

How much money does Olema Pharmaceuticals make?

Olema Pharmaceuticals has a market capitalization of $1.52 billion.

What is Olema Pharmaceuticals' official website?

The official website for Olema Pharmaceuticals is www.olema.com.

Where are Olema Pharmaceuticals' headquarters?

Olema Pharmaceuticals is headquartered at 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107.

How can I contact Olema Pharmaceuticals?

Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The company can be reached via phone at 415-651-3316 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.